Biota Pharmaceuticals to Host Conference Call to Report Third Quarter Fiscal Year 2015 Financial Results
April 30 2015 - 4:01PM
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA), a biopharmaceutical
company focused on the discovery and development of products to
prevent and treat serious and potentially life-threatening viral
respiratory infectious diseases, announced today that it will host
a conference call on Thursday, May 7, 2015 at 9:00 a.m. ET to
review the Company's third quarter fiscal year financial results
and provide an update on recent corporate developments. The Company
will issue a press release summarizing its financial results the
same day, prior to the conference call.
In order to participate in the conference call, please dial
(877) 312-5422 (domestic) or (253) 237-1122 (international) and
refer to conference ID number 33437959. The live webcast can be
accessed under the Investors section of the Company's website at
www.biotapharma.com or you may use the link:
http://edge.media-server.com/m/p/mqdyq7jk.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals, Inc. is a company focused on the
discovery and development of products to treat serious viral
respiratory infectious diseases. The Company currently has two
clinical-stage Phase 2 product candidates: (i) laninamivir
octanoate, which is being developed as a one-time treatment for
influenza A and B infections; and (ii) vapendavir, a potent, broad
spectrum capsid inhibitor of enteroviruses in development for the
treatment of human rhinovirus infected patients with underlying
respiratory illnesses, such as moderate-to-severe asthma and
chronic obstructive pulmonary disease (COPD). The Company is also
conducting IND-enabling studies with BTA-C585, an orally
bioavailable F protein inhibitor, in development for the treatment
of respiratory syncytial virus infections. For additional
information about the Company, please visit
www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
CONTACT: Joseph M. Patti, PhD
President and Chief Executive Officer
(678) 221-3351
j.patti@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(267) 909-9237
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024